Skip to main content

Our Company

Story & Identity

MDoloris Medical Systems is a French medtech created in 2010 through a public-private partnership based on the work of Pr. Régis LOGIER, Dr. MATHIEU JEANNE, Julien DE JONCKHEERE & Dr. Michel DELECROIX  (INSERM Unit 807 – CIC-IT at University Hospital).


The founding R&D link has been particularly strong throughout these years of privileged collaboration continues with this world-renowned team.

MDoloris’ innovation, its scientific and medical breakthrough, has been to research, evaluate and validate a new biological measure, a new physiological datum for measuring pain or perceived suffering.

And it is the instantaneous measurement of the autonomic nervous system’s response to painful stimuli, through the continuous measurement of cardiac variability, that has provided us today with a simple indicator, a number from 1 to 100, representing the parasympathetic tone of the human body.

This new reference beacon is obviously of great importance in certain specific circumstances, particularly in surgery.


This technology has given a rise to MDoloris products, mainly used in neonatal monitoring and in adult and pediatric anesthesiology.


MDoloris’ proprietary and patented technology has been the subject of more than 230 independent international scientific publications. Today, more than half a million hospital patients have already benefited from this technology.

After successfully developing the MDoloris technology and an assessment index (ANI-NIPE) for unconscious patients, MDoloris turned its attention to adapting its MDoloris technology to other living conditions and transposed the technology and the assessment of the autonomic nervous system to the conscious patient, again with a view to assessing comfort and well-being.
This new phase of R&D has recently opened up new prospects in hospitals (monitoring in intensive care with the development of an additional index - vital energy) and outside (portable device for nursing homes, palliative care, etc).

The Vision

Today, the patented and proprietary MDoloris Technology is based on solid scientific and clinical foundations and takes anesthesiology and the assessment of patient comfort / suffering to a new level, offering greater safety and objective continuous monitoring.

MDoloris Technology is changing day-to-day practice in a wide range of medical fields and procedures and offers many opportunities for today and for the future as it enables pain and comfort to be assessed objectively, whether the patient is conscious or unconscious.

The Pipeline

MDoloris Technology’s ANS monitoring holds the potential to transform pain management, patient comfort, and personalized care across many fields of applications such as surgical, intensive care and palliative care settings.

As research progresses, and technology evolves, it is likely that we will see more advanced devices in the coming years.

In partnership with the Lille University Hospital, MDoloris is the first company to able to integrate an analgesic autonomous loop system.
This advancement will allow MDoloris Technology to benefit from physiological and automatic feedback to control and optimize the tone of the autonomic nervous system and therefore optimize support anesthetists during surgery. This achievement will mark a significant step forward in anesthesiology, enhancing patient safety, control, and comfort, and allowing anesthetists to focus on other vital parameters.

Additionally, there are many other fields of interest.
Let’s explore how MDoloris technology and autonomic nervous system (ANS) monitoring could evolve in various medical contexts in the coming years.

during surgery

Closed-loop control of nociception
Integration with surgical robots

Intensive care
patient comfort

Early detection of discomfort
Personalised sedation management
Prediction of mortality risk

Monitoring comfort in palliative and alzheimer’s care

Objective assessment of comfort
Behavioural insights
Wearable devices
Integration with telemedicine

  1. Agosto, A. (2024). Surgical robotics: Leveraging hardware and AI to improve patient care. Global X.
  2. Knudsen, J. E., Ghaffar, U., Ma, R., & Hung, A. J. (2024). Clinical applications of artificial intelligence in robotic surgery. *Springer*.
  3. Kobayashi, N., Shiga, T., Ikumi, S., Watanabe, K., Murakami, H., & Yamauchi, M. (2021). Semi-automated pain tracking in intensive care patients using artificial intelligence: A retrospective observational study. Scientific Reports.
  4. Marcos-Vidal, J. M., González, R., Merino, M., Higuera, E., & García, C. (2023). Sedation in patients with sepsis: towards a personalised approach. *Journal of Personalised Medicine*.
  5. Bauschert, L., & Prod'homme, C. (2021). Assessing comfort at the end of life, is the clinic sufficient? A retrospective cohort study of combined comfort assessment with analgesia/nociception index and clinic in non-communicative patients. Journal of Palliative Care, 39(2).
  6. Turcu, A.-M., Ilie, A. C., Ștefăniu, R., Țăranu, S. M., Sandu, I. A., Alexa-Stratulat, T., Pîslaru, A. I., & Alexa, I. D. (2023). The impact of heart rate variability monitoring on the prevention of major cardiovascular events. Diagnostics.
  7. Sharma, S., Rawal, R., & Shah, D. (2023). Overcoming the challenges of AI-based telemedicine: Best practices and lessons learned. *Journal of Education and Health Promotion.

Our Team

MDoloris Management

“Our company’s motto, measure the autonomic nervous system, take control and improve outcomes; has been driving each member of the MDoloris Medical Systems team since the company’s inception in June 2010.

Since day one, MDoloris has overcome many obs­tacles thanks to our exceptionally dedicated team members. Yet we have still delivered even during the Covid crisis. This team dedication is the foun­dation of our success.”

Fabien PAGNIEZCEO Founder

Fabien Pagniez

CEO, Founder

Ignacio Gonzalez

Chief Medical Officer

Julien Legrand

Chief Financial Officer

Jean-Marc Mosselmans

Strategic & Marketing Director

Board Members